Autopsy report · NCT06071624

Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.

“Trial being transferred to new lead site”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months before it started.
• Suspended: paused, and may or may not restart.
• 30 participants planned (an estimate, not an actual count).

Vital statistics

Status

Suspended

Phase

Phase 1

Sponsor

Huda Salman

Sponsor type

University, hospital or other

Conditions

Chronic Myelomonocytic Leukemia

Interventions

CD4CAR

Participants

30 (planned, not actual)

Sites

4

Countries

United States

Trials that died the same way

• A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of MEDI-538 in Adults With B-Cell Chronic Lymphocytic Leukemia (CLL)
  “Replacing this trial with a new trial.” (58% match in meaning)
• Photodynamic Therapy (PDT) Trial for Palliation of Cholangiocarcinoma
  “PI relocated and reopened trial in new university” (55% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.